Antonio Guglietta – författare

The application of molecular techniques to gastroenterology continues to yield important advances in the development of drugs to treat gastrointestinal disorders. Important new drugs have emerged through the collaborative and complementary efforts of basic scientists, clinicians, and clinical researchers in academia and the pharmaceutical industry. The challenge has been exciting, with a few surprises along the way. Consider peptic ulcer disease as an example. The discovery of H receptors and the availability of potent and 2 selective H-receptor antagonists signaled the beginning of a new era 2 in the treatment of gastric hypersecretory states and peptic ulcers. Introduction of proton pump inhibitors offered another therapeutic option. Though H-receptor antagonists and proton pump inhibitors 2 are important and useful drugs, the discovery of the link between H. pylori infection and peptic ulcer disease has led to even more effective pharmacotherapeutic regimens. Our intent in Drug Development: Molecular Targets for GI Diseases is to bring together hands-on experts to review promising areas of gastrointestinal pharmacology. The contemporary topics covered, from a mechanistic viewpoint, are relevant to gastrointestinal inflammation and motility disorders. Authoritative opinions are offered on both future research directions and potential applications for new therapies.

The application of molecular techniques to gastroenterology continues to yield important advances in the development of drugs to treat gastrointestinal disorders. Important new drugs have emerged through the collaborative and complementary efforts of basic scientists, clinicians, and clinical researchers in academia and the pharmaceutical industry. The challenge has been exciting, with a few surprises along the way. Consider peptic ulcer disease as an example. The discovery of H receptors and the availability of potent and 2 selective H-receptor antagonists signaled the beginning of a new era 2 in the treatment of gastric hypersecretory states and peptic ulcers. Introduction of proton pump inhibitors offered another therapeutic option. Though H-receptor antagonists and proton pump inhibitors 2 are important and useful drugs, the discovery of the link between H. pylori infection and peptic ulcer disease has led to even more effective pharmacotherapeutic regimens. Our intent in Drug Development: Molecular Targets for GI Diseases is to bring together hands-on experts to review promising areas of gastrointestinal pharmacology. The contemporary topics covered, from a mechanistic viewpoint, are relevant to gastrointestinal inflammation and motility disorders. Authoritative opinions are offered on both future research directions and potential applications for new therapies.

In recent years, the area of pharmacotherapy of GI inflammation has witnessed important progress, with new drugs and therapeutic approaches being introduced. The volume reviews the pharmacotherapy of selected gastrointestinal inflammatory conditions chosen on the basis of their clinical importance and/or the areas where important and exciting progress has been made recently. Besides discussing current pharmacotherapy to treat the most important GI inflammation conditions, the book also indicates possible future therapeutic avenues likely to become available in a few years.The book is of interest to various sectors of the scientific community ranging from clinicians to pharmacologists and from biochemists to microbiologists, who will find it a useful tool for their clinical practice and research activity.

Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.

Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.